Commonwealth Fund April 7, 2021
Kristi Martin

Toplines

Since the FDA established its accelerated approval program in 1992, it has approved 253 drugs without clear evidence of their health benefits

Public and private insurers are paying billions of dollars for drugs that have not demonstrated improved health benefits for patients

An important conversation is emerging on how public and private insurers pay for prescription drugs with limited clinical evidence. This discussion is focusing on drugs approved under the U.S. Food and Drug Administration’s (FDA) accelerated approval program, in which drugs can come to market without clearly proving health outcomes. A primary concern is that insurers and government are paying high prices for drugs that have not demonstrated they improve health outcomes for patients. Policymakers are considering options...

Today's Sponsors

Teladoc Health
Premier
TripleTree

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

HLTH

 
Topics: Biotechnology, FDA, Govt Agencies, Insurance, Pharma, Pharma / Biotech
NIH to test repurposing up to 7 drugs to treat COVID-19 symptoms at home
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19
The FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
To Improve Competition In Generic Drug Markets, The FDA Should Discount User Fees For Small Players
Designing better antibody drugs with artificial intelligence